Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer clinical trials

Explore recruiting estrogen receptor positive her2 negative advanced breast cancer clinical trials.

Recruiting estrogen receptor positive her2 negative advanced breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer

Belgium, Hungary, France, Italy, Portugal, Spain +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

SERENA-4: A Randomised, Multicentre, Double-Blind, Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Slovakia, Spain, Austria, Czechia, Germany, France +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase III, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, both Combined with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy

Slovenia, Finland, Belgium, Germany, France, Greece +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4891001 - A Phase 3, Randomized, Open-Label, Multicenter Trial Of Arv-471 (PF-07850327) vs Fulvestrant In participants With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment For Advanced Disease (VERITAC-2)

Hungary, Spain, Austria, Germany, France, Czechia +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer trials by city

Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Toronto Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Vancouver Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Montreal Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Calgary Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Edmonton Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Ottawa Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Winnipeg Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Quebec City Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Hamilton Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Kitchener Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in London Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Halifax Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in New York Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Los Angeles Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Chicago Estrogen Receptor Positive Her2 Negative Advanced Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease